eligibility_summary
Eligibility: Relapsed/refractory multiple myeloma with measurable disease, ≥3 prior lines including a PI, IMiD, and anti‑CD38, ECOG 0–1, adequate hematologic, renal, hepatic, pulmonary, and cardiac function. Exclusions: prior CAR‑T, auto SCT <6 wks or allo SCT <6 mos before lymphodepletion, CNS involvement, stroke/seizure <6 mos, HIV, live vaccine <4 wks, hepatitis B/C, allergy to CB‑011 or its excipients.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CB-011, a CRISPR-edited, allogeneic anti-BCMA CAR-T cell therapy (cellular immunotherapy). Mechanism: donor T cells are engineered to express a CAR that binds BCMA on malignant plasma cells, triggering T-cell activation and cytotoxic killing. Lymphodepletion: cyclophosphamide (alkylating chemotherapy) and fludarabine (purine analog) are given to deplete host lymphocytes and support CAR-T expansion. Targets/cells/pathways: BCMA (B-cell maturation antigen) on plasma cells, engagement of CAR signaling to activate T-cell effector pathways against multiple myeloma. Phase 1 dose escalation/expansion in relapsed/refractory MM.